Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelin receptor antagonists (ERAs) counteract the effects of endothelins, potent vasoactive peptides that contribute to PAH. By blocking endothelin receptors, ERAs reduce vasoconstriction in pulmonary arteries, alleviating symptoms and slowing disease progression. This mechanism makes them a key therapeutic strategy for managing PAH.

Endothelin-converting enzyme (ECE) catalyzes the synthesis of endothelins through a complex enzymatic sequence. ECE-1 specifically acts as the rate-limiting step in producing ET-1, the predominant form of endothelin in the body. This critical enzymatic control point makes ECE-1 essential to understanding endothelin production and PAH pathophysiology.

Bosentan and macitentan are non-selective antagonists blocking both ETA and ETB receptors, effectively reducing PAH progression. Ambrisentan selectively inhibits only the ETA receptor, providing a more targeted approach. All three are oral medications, but their receptor selectivity differs, offering clinicians varied treatment options.

Common side effects include headache, pulmonary edema (fluid accumulation in the lungs), nasal congestion, and pharyngitis. Additionally, these drugs can elevate liver transaminases, indicating potential liver damage. Patients with moderate-to-severe liver disease should avoid ERAs due to this hepatotoxic risk.

Endothelin receptor antagonists must be avoided during pregnancy due to their potential to cause fetal harm. Women of childbearing age prescribed these medications should use effective contraception during and after treatment. This teratogenic risk makes pregnancy status a critical consideration before initiating ERA therapy.

ET-1 interacts with both ETA and ETB receptors, triggering vasoconstriction and vasodilation in pulmonary arteries. These opposing effects significantly impact blood pressure and contribute to PAH pathology. Understanding receptor-specific responses helps explain why selective versus non-selective antagonists produce different therapeutic outcomes.

Endothelin receptor antagonists represent one therapeutic strategy among several treatment for pulmonary arterial hypertension options. Other approaches include phosphodiesterase inhibitors, prostacyclin receptor agonists, and receptor tyrosine kinase inhibitors. Each class targets different pathways in PAH pathophysiology, allowing combination or sequential therapy.